Dr Kate Vandyke
Research Fellow (B) (with PhD)
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am currently a Cancer Council SA Beat Cancer Early Career Research Fellow and co-lead of the Myeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Precision Medicine Theme.
My research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.https://aurora.adelaide.edu.au/userprofile.html?uid=3778&em=true#
My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.
Current projects include:
- Defining major cellular and molecular mechanisms that drive tumour dissemination in multiple myeloma
- Identifying how changes to the myeloma bone marrow microenvironment drive disease progression for MGUS and smouldering myeloma to multiple myeloma
- Identification of novel serum biomarkers that enable the identification of high-risk MGUS, smouldering myeloma and multiple myeloma patients
- Using novel drug delivery strategies to increase tumour-specific drug uptake and decrease off-target side-effects in multiple myeloma
- Identification of novel therapeutic targets for the treatment of high-risk multiple myeloma
-
Appointments
Date Position Institution name 2020 - ongoing Senior research fellow South Australian Health and Medical Research Institute 2018 - ongoing Beat Cancer Early Career Research Fellow University of Adelaide, Adelaide 2017 - 2018 Post-doctoral Research Scientist University of Adelaide, Adelaide 2013 - 2016 Mary Overton Early Career Research Fellow SA Pathology 2012 - 2018 Affiliate Lecturer University of Adelaide 2012 - 2013 Multiple Myeloma Research Foundation Research Fellow SA Pathology 2010 - 2012 Post-doctoral Research Scientist SA Pathology 2007 - 2010 Technical assistant (part time) SA Pathology 2005 - 2006 Research Assistant Prince of Wales Hospital -
Education
Date Institution name Country Title 2007 - 2010 University of Adelaide Australia PhD 2000 - 2004 University of New South Wales Australia BMedSci (Hons) -
Research Interests
-
Journals
Year Citation 2024 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Wallington-Gates, C. T., Spencer, A., . . . Zannettino, A. C. W. (2024). Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leukemia Research, 139, 107469.
2023 Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
Europe PMC12023 Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023). Mesenchymal stromal cell senescence in haematological malignancies. Cancer and Metastasis Reviews, 42(1), 277-296.
Scopus12 WoS2 Europe PMC52022 Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240.
Scopus10 WoS8 Europe PMC92021 Opperman, K. S., Vandyke, K., Psaltis, P. J., Noll, J. E., & Zannettino, A. C. W. (2021). Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer and Metastasis Reviews, 40(1), 273-284.
Scopus11 WoS11 Europe PMC102021 Vandyke, K. (2021). Seed and soil revisited in multiple myeloma.. Blood, 137(17), 2282-2283.
Scopus1 Europe PMC12020 Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.. PLoS One, 15(1), e0228408.
WoS2 Europe PMC12020 Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108.
Scopus21 WoS20 Europe PMC132020 Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353.
Scopus4 WoS3 Europe PMC52020 Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20.
Scopus6 WoS5 Europe PMC32020 Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2(9), 554-572.
Scopus4 WoS1 Europe PMC32020 Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187.
Scopus13 WoS8 Europe PMC82020 Zeissig, M. N., Zannettino, A. C. W., & Vandyke, K. (2020). Tumour dissemination in multiple myeloma disease progression and relapse: A potential therapeutic target in high-risk myeloma. Cancers, 12(12), 3643-1-3643-20.
Scopus6 WoS6 Europe PMC62019 Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., . . . Croucher, P. I. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43.
Scopus95 WoS73 Europe PMC722019 Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787.
Scopus51 WoS44 Europe PMC372018 Mrozik, K., Blaschuk, O., Cheong, C., Zannettino, A., & Vandyke, K. (2018). N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 18(1), 1-16.
Scopus220 WoS193 Europe PMC1402017 Hemming, S., Cakouros, D., Codrington, J., Vandyke, K., Arthur, A., Zannettino, A., & Gronthos, S. (2017). EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture & structural integrity and accelerates remodeling. FASEB Journal, 31(3), 1011-1027.
Scopus48 WoS41 Europe PMC362017 Vuckovic, S., Vandyke, K., Rickards, D., McCauley Winter, P., Brown, S., Mitchell, T., . . . Hutchinson, A. (2017). The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. British Journal of Haematology, 177(3), 423-440.
Scopus24 WoS21 Europe PMC162017 Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616.
Scopus38 WoS34 Europe PMC242017 Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
Scopus42 WoS37 Europe PMC302017 Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981.
Scopus16 WoS12 Europe PMC122016 Hemming, S., Cakouros, D., Vandyke, K., Davis, M. J., Zannettino, A. C. W., & Gronthos, S. (2016). Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells and Development, 25(12), 909-921.
Scopus59 WoS55 Europe PMC402016 Ng, J., Hynes, K., White, G., Sivanathan, K., Vandyke, K., Bartold, P., & Gronthos, S. (2016). Immunomodulatory properties of induced pluripotent stem cell-derived mesenchymal cells. Journal of Cellular Biochemistry, 117(12), 2844-2853.
Scopus32 WoS30 Europe PMC252015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
Scopus25 WoS26 Europe PMC232015 Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399.
Scopus27 WoS22 Europe PMC232015 Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16.
Scopus27 WoS25 Europe PMC212015 Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354.
Scopus32 WoS28 Europe PMC232014 Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585.
Scopus34 WoS31 Europe PMC302014 Ahmed, F., Dutta, N., Zannettino, A., Vandyke, K., & Choudhury, N. (2014). Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules, 15(4), 1276-1287.
Scopus18 WoS15 Europe PMC82013 Vandyke, K., Chow, A., Williams, S., To, L., & Zannettino, A. (2013). Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 161(4), 499-507.
Scopus16 WoS18 Europe PMC162013 Arthur, A., Panagopoulos, R., Cooper, L., Menicanin, D., Parkinson, I., Codrington, J., . . . Gronthos, S. (2013). EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 28(4), 926-935.
Scopus39 WoS35 Europe PMC272013 Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76.
Scopus23 WoS22 Europe PMC192012 Fitter, S., Vandyke, K., Gronthos, S., & Zannettino, A. (2012). Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 48(3), 229-240.
Scopus52 WoS46 Europe PMC472011 Vandyke, K., Fitter, S., & Zannettino, A. (2011). The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 1(2), E2.
Scopus22 WoS21 Europe PMC82010 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Schultz, C., Sims, N., & Zannettino, A. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770.
Scopus83 WoS73 Europe PMC602010 Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767.
Scopus50 WoS46 Europe PMC412010 Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774.
Scopus122 WoS107 Europe PMC772009 Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159.
Scopus34 WoS32 Europe PMC302009 Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997.
Scopus49 WoS47 Europe PMC352007 Vandyke, K., White, M. Y., Nguyen-Khuong, T., Ow, K., Luk, S. C. W., Kingsley, E. A., . . . Russell, P. J. (2007). Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo. Neoplasia, 9(4), 322-331.
Scopus8 WoS8 Europe PMC62007 Vandyke, K., Jackson, P., Rowe, A., Russell, P. J., & Blair, J. M. (2007). Androgen decreases osteoprotegerin expression in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 10(2), 160-166.
Scopus2 WoS3 Europe PMC11986 VANDYKE, K., & VANDYKE, C. (1986). CELLULAR CHEMILUMINESCENCE ASSOCIATED WITH DISEASE STATES. METHODS IN ENZYMOLOGY, 133, 493-507.
WoS62 Europe PMC131985 EDINBORO, L. E., VANDYKE, K., PEDEN, D., CASTRANOVA, V., & WIERDA, D. (1985). STUDIES OF LUMINOL-DEPENDENT WHOLE-BLOOD CHEMI-LUMINESCENCE INDUCED BY PLATELET-ACTIVATING FACTOR (PAF). MICROCHEMICAL JOURNAL, 31(3), 261-271.
WoS11985 PEDEN, D., VANDYKE, K., EDINBORO, L., WIERDA, D., & CASTRANOVA, V. (1985). THE MEASUREMENT OF CHEMI-LUMINESCENCE, AGGREGATION, AND 5-HYDROXY-6,8,11,14-EICOSATETRAENOIC ACID PRODUCTION OF NORMAL-FORMYL-METHIONINYL-LEUCYL-PHENYLALANINE-STIMULATED HUMAN POLYMORPHONUCLEAR LEUKOCYTES. MICROCHEMICAL JOURNAL, 31(1), 22-28.
WoS21984 CASTRANOVA, V., & VANDYKE, K. (1984). ANALYSIS OF OXIDATION OF THE MEMBRANE-POTENTIAL PROBE, DI-S-C3(5), DURING GRANULOCYTE ACTIVATION. MICROCHEMICAL JOURNAL, 29(2), 151-161.
WoS71984 VANDYKE, K., CASTRANOVA, V., VANDYKE, C. J., MA, J., MICHAUX, K., MOLLISON, K. W., & CARTER, G. W. (1984). GRANULOCYTE RESPONSE TO OXIDIZED FMLP - EVIDENCE FOR PARTIAL INACTIVATION OF FMLP. INFLAMMATION, 8(1), 87-99.
WoS5 Europe PMC31983 PEKOE, G. M., PEDEN, D., & VANDYKE, K. (1983). IMPAIRMENT OF LEUKOCYTE MYELOPEROXIDASE BACTERICIDAL MECHANISMS WITH KETAMINE (KETALAR). AGENTS AND ACTIONS, 13(1), 59-62.
WoS11 Europe PMC51983 PEDEN, D., VANDYKE, K., PEKOE, G., & CASTRANOVA, V. (1983). TEMPORAL SEQUENCE OF CHEMI-LUMINESCENCE AND AGGREGATION OF HUMAN-NEUTROPHILS AND PLATELETS AFTER STIMULATION BY ARACHIDONIC-ACID. MICROCHEMICAL JOURNAL, 28(1), 91-98.
WoS41983 VANDYKE, K., MATAMOROS, M., VANDYKE, C. J., & CASTRANOVA, V. (1983). CALCIUM IONOPHORE-STIMULATED CHEMI-LUMINESCENCE (CL) FROM HUMAN-GRANULOCYTES - EVIDENCE THAT A23187-INDUCED CHEMI-LUMINESCENCE ORIGINATES FROM ARACHIDONIC-ACID METABOLISM. MICROCHEMICAL JOURNAL, 28(4), 568-579.
WoS51983 MATAMOROS, M. C., WALKER, B. K., VANDYKE, K., & VANDYKE, C. J. (1983). EFFECT OF CANCER CHEMOTHERAPEUTIC-AGENTS ON THE CHEMI-LUMINESCENCE OF HUMAN-GRANULOCYTES. PHARMACOLOGY, 27(1), 29-39.
WoS11 Europe PMC71982 VANDYKE, K., PEDEN, D., VANDYKE, C., JONES, G., CASTRANOVA, V., & MA, J. (1982). INHIBITION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS OF LUMINOL-DEPENDENT HUMAN-GRANULOCYTE CHEMI-LUMINESCENCE AND [H-3]-LABELED FMLP BINDING - EFFECT OF SULINDAC SULFIDE, INDOMETHACIN METABOLITE, AND OPTICAL ENANTIOMERS (+)MK830 AND (-)MK830. INFLAMMATION, 6(1), 113-125.
WoS28 Europe PMC171982 PEKOE, G., VANDYKE, K., MENGOLI, H., PEDEN, D., & ENGLISH, D. (1982). COMPARISON OF THE EFFECTS OF ANTIOXIDANT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AGAINST MYELOPEROXIDASE AND HYPOCHLOROUS ACID LUMINOL-ENHANCED CHEMI-LUMINESCENCE. AGENTS AND ACTIONS, 12(1-2), 232-238.
WoS40 Europe PMC251982 PEKOE, G., VANDYKE, K., PEDEN, D., MENGOLI, H., & ENGLISH, D. (1982). ANTI-OXIDATION THEORY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS BASED UPON THE INHIBITION OF LUMINOL-ENHANCED CHEMI-LUMINESCENCE FROM THE MYELOPEROXIDASE REACTION. AGENTS AND ACTIONS, 12(3), 371-376.
WoS53 Europe PMC331982 VANDYKE, K., PEKOE, G., PEDEN, D., MENGOLI, H., CASTRANOVA, V., & ENGLISH, D. (1982). MULTIPURPOSE RADIOMATIC AUTOMATED FLOW LIQUID SCINTILLATION-COUNTER SYSTEM FOR MEASUREMENT OF BURST OR DELAYED CHEMI-LUMINESCENCE REACTIONS - MODEL-DRUG INHIBITION WITH LUMINOL-DEPENDENT MYELOPEROXIDASE. MICROCHEMICAL JOURNAL, 27(2), 276-289.
WoS11982 PEKOE, G., VANDYKE, K., & PEDEN, D. (1982). A NOVEL METHOD FOR MEASURING INITIAL-BURST CHEMI-LUMINESCENCE IN A LIQUID SCINTILLATION-COUNTER USING THE MYELOPEROXIDASE-H2O2-CL-REACTION. MICROCHEMICAL JOURNAL, 27(2), 221-230.
WoS21981 JONES, G. S., VANDYKE, K., & CASTRANOVA, V. (1981). TRANSMEMBRANE POTENTIAL CHANGES ASSOCIATED WITH SUPEROXIDE RELEASE FROM HUMAN-GRANULOCYTES. JOURNAL OF CELLULAR PHYSIOLOGY, 106(1), 75-83.
WoS53 Europe PMC291981 UDEINYA, I. J., & VANDYKE, K. (1981). PLASMODIUM-FALCIPARUM - SYNTHESIS OF GLYCOPROTEIN BY CULTURED ERYTHROCYTIC STAGES. EXPERIMENTAL PARASITOLOGY, 52(3), 297-302.
WoS4 Europe PMC31981 UDEINYA, I. J., & VANDYKE, K. (1981). CONCURRENT INHIBITION BY TUNICAMYCIN OF GLYCOSYLATION AND PARASITEMIA IN MALARIAL PARASITES (PLASMODIUM, FALCIPARUM) CULTURED IN HUMAN-ERYTHROCYTES. PHARMACOLOGY, 23(3), 165-170.
WoS16 Europe PMC121981 CASTRANOVA, V., JONES, G. S., PHILLIPS, R. M., PEDEN, D., & VANDYKE, K. (1981). ABNORMAL RESPONSES OF GRANULOCYTES IN CHRONIC GRANULOMATOUS-DISEASE. BIOCHIMICA ET BIOPHYSICA ACTA, 645(1), 49-53.
WoS23 Europe PMC101981 UDEINYA, I. J., & VANDYKE, K. (1981). 2-DEOXYGLUCOSE - INHIBITION OF PARASITEMIA AND OF GLUCOSAMINE INCORPORATION INTO GLYCOSYLATED MACROMOLECULES, IN MALARIAL PARASITES (PLASMODIUM, FALCIPARUM). PHARMACOLOGY, 23(3), 171-175.
WoS19 Europe PMC171980 JONES, G. S., VANDYKE, K., & CASTRANOVA, V. (1980). PURIFICATION OF HUMAN-GRANULOCYTES BY CENTRIFUGAL ELUTRIATION AND MEASUREMENT OF TRANSMEMBRANE POTENTIAL. JOURNAL OF CELLULAR PHYSIOLOGY, 104(3), 425-431.
WoS31 Europe PMC161980 UDEINYA, I. J., & VANDYKE, K. (1980). LABELING OF MEMBRANE-GLYCOPROTEINS OF CULTIVATED PLASMODIUM-FALCIPARUM. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 58(3), 445-448.
WoS14 Europe PMC81980 VANDYKE, K., VANDYKE, C., PEDEN, D., JONES, G., CASTRANOVA, V., BRESTEL, E., & RINGROSE, M. (1980). LUMINOL-DEPENDENT CHEMI-LUMINESCENCE ANALYSIS OF HUMAN-PLATELETS. MICROCHEMICAL JOURNAL, 25(4), 514-523.
WoS71979 NUZEM, R. A., VANDYKE, K., & FLINK, E. B. (1979). USE OF THE LUCIFERIN-LUCIFERASE SYSTEM TO MEASURE SERUM MAGNESIUM - INHIBITION OF LIGHT PRODUCTION BY HEPARIN AND FATTY-ACIDS. MICROCHEMICAL JOURNAL, 24(4), 409-420.
WoS61979 VANDYKE, K., VANDYKE, C., UDEINYA, J., BRISTER, C., & WILSON, M. (1979). NEW SCREENING SYSTEM FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS BASED UPON INHIBITION OF CHEMI-LUMINESCENCE PRODUCED FROM HUMAN-CELLS (GRANULOCYTES). CLINICAL CHEMISTRY, 25(9), 1655-1661.
WoS57 Europe PMC271978 WILSON, M. E., TRUSH, M. A., VANDYKE, K., KYLE, J. M., MULLETT, M. D., & NEAL, W. A. (1978). LUMINOL-DEPENDENT CHEMILUMINESCENCE ANALYSIS OF OPSONOPHAGOCYTIC DYSFUNCTIONS. JOURNAL OF IMMUNOLOGICAL METHODS, 23(3-4), 315-326.
WoS521978 URQUILLA, P. R., VANDYKE, K., & TRUSH, M. (1978). STRUCTURE-ACTIVITY RELATION OF PYRIMIDINE NUCLEOTIDES AND NUCLEOSIDE IN CANINE ISOLATED CEREBRAL VESSELS. JOURNAL OF PHARMACY AND PHARMACOLOGY, 30(3), 189-190.
WoS9 Europe PMC51978 WILSON, M. E., TRUSH, M. A., VANDYKE, K., & NEAL, W. (1978). INDUCTION OF CHEMILUMINESCENCE IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES BY CALCIUM IONOPHORE-A23187. FEBS LETTERS, 94(2), 387-390.
WoS21 Europe PMC161978 STEVENS, P., WINSTON, D. J., & VANDYKE, K. (1978). INVITRO EVALUATION OF OPSONIC AND CELLULAR GRANULOCYTE FUNCTION BY LUMINOL-DEPENDENT CHEMILUMINESCENCE - UTILITY IN PATIENTS WITH SEVERE NEUTROPENIA AND CELLULAR DEFICIENCY STATES. INFECTION AND IMMUNITY, 22(1), 41-51.
WoS198 Europe PMC911977 VANDYKE, K., WILSON, M., TRUSH, M., TAYLOR, M., & STEALEY, P. (1977). PLASMODIUM-BERGHEI - HIGH-PRESSURE LIQUID-CHROMATOGRAPHIC ANALYSIS OF NUCLEOTIDES FROM ERYTHROCYTE-FREE MALARIAL PARASITES. EXPERIMENTAL PARASITOLOGY, 42(2), 274-281.
WoS11977 VANDYKE, K., TRUSH, M., WILSON, M., STEALEY, P., & MILES, P. (1977). LUMINOL-DEPENDENT CHEMILUMINESCENCE ANALYSIS OF CELLULAR AND HUMORAL DEFECTS OF PHAGOCYTOSIS USING A CHEM-GLO PHOTOMETER. MICROCHEMICAL JOURNAL, 22(4), 463-474.
WoS731976 TRUSH, M. A., & VANDYKE, K. (1976). EFFICIENT INEXPENSIVE MULTISLEEVE LIQUID SCINTILLATION-COUNTING SYSTEM. MICROCHEMICAL JOURNAL, 21(1), 70-74.
WoS11975 VANDYKE, K. (1975). GUANOSINE TETRAPHOSPHATE AND PENTAPHOSPHATE ANALYSIS - PEI-CELLULOSE THIN-LAYER PURIFICATION AND LUCIFERIN-LUCIFERASE LIQUID SCINTILLATION QUANTITATION. MICROCHEMICAL JOURNAL, 20(3), 379-387.
WoS11975 MANANDHAR, M. S. P., & VANDYKE, K. (1975). DETAILED PURINE SALVAGE METABOLISM IN AND OUTSIDE FREE MALARIAL PARASITE. EXPERIMENTAL PARASITOLOGY, 37(2), 138-146.
WoS41 Europe PMC261975 VANDYKE, K. (1975). COMPARISON OF TRITIATED HYPOXANTHINE, ADENINE AND ADENOSINE FOR PURINE-SALVAGE INCORPORATION INTO NUCLEIC-ACIDS OF MALARIAL PARASITE, PLASMODIUM-BERGHEI. TROPENMEDIZIN UND PARASITOLOGIE, 26(2), 232-238.
WoS14 Europe PMC61975 CROUTHAMEL, W. G., & VANDYKE, K. (1975). PROBLEM IN LIQUID SCINTILLATION-COUNTING - ADSORPTION OF [C-14] POLYETHYLENE-GLYCOL IN DILUTE-SOLUTIONS. ANALYTICAL BIOCHEMISTRY, 66(1), 234-242.
WoS4 Europe PMC31974 MANANDHAR, M. S., & VANDYKE, K. (1974). GUANOSINE TRIPHOSPHATE ANALYSIS - PEI-THIN LAYER PURIFICATION AND LUCIFERIN-LUCIFERASE LIQUID SCINTILLATION QUANTITATION. ANALYTICAL BIOCHEMISTRY, 60(1), 122-129.
WoS14 Europe PMC101974 MANANDHAR, M. S., & VANDYKE, K. (1974). DELAYED LUMINESCENCE ANALYSIS (DLA) OF PURINE AND PYRIMIDINE RIBOSE AND DEOXYRIBOSE NUCLEOTIDE TRIPHOSPHATES IN PICOMOLE QUANTITIES. MICROCHEMICAL JOURNAL, 19(1), 42-51.
WoS91974 MANANDHAR, M. S., & VANDYKE, K. (1974). ADENOSINE TETRAPHOSPHATE ANALYSIS - POLYETHYLENEIMINE (PEI) THIN-LAYER PURIFICATION AND FIREFLY-EXTRACT LIQUID SCINTILLATION QUANTITATION. ANALYTICAL BIOCHEMISTRY, 58(2), 368-375.
WoS17 Europe PMC61973 CARTER, G. W., & VANDYKE, K. (1973). SCINTILLATION COUNTING - COMPARISON OF COUNTING EFFICIENCIES OF SEVERAL AQUEOUS SOLUBILIZERS. ANALYTICAL BIOCHEMISTRY, 54(2), 624-627.
WoS24 Europe PMC171972 CARTER, G., & VANDYKE, K. (1972). DRUG EFFECTS ON PHOSPHORYLATION OF ADENOSINE AND ITS INCORPORATION INTO NUCLEIC-ACIDS OF CHLOROQUINE SENSITIVE AND RESISTANT ERYTHROCYTE-FREE MALARIAL PARASITES. PROCEEDINGS OF THE HELMINTHOLOGICAL SOCIETY OF WASHINGTON, 39(NOV), 244-249.
WoS111971 CARTER, G. W., & VANDYKE, K. (1971). SUPERIOR COUNTING SOLUTION FOR WATER-SOLUBLE TRITIATED COMPOUNDS. CLINICAL CHEMISTRY, 17(7), 576-&.
WoS32 Europe PMC211970 VANDYKE, K., LANTZ, C., & SZUSTKIEWICZ, C. (1970). QUINACRINE - MECHANISMS OF ANTIMALARIAL ACTION. SCIENCE, 169(3944), 492-+.
WoS33 Europe PMC91969 VANDYKE, K., STITZEL, R., MCCLELLA, T., & SZUSTKIE, C. (1969). AN AUTOMATED PROCEDURE FOR SENSITIVE AND SPECIFIC DETERMINATION OF ATP. CLINICAL CHEMISTRY, 15(1), 3-&.
WoS21 Europe PMC61969 VANDYKE, K., & SZUSTKIEWICZ, C. (1969). AN AUTOMATED DETECTION SYSTEM FOR MOST L-ALPHA-AMINO ACIDS. CLINICAL CHEMISTRY, 15(2), 154-+.
WoS11 Europe PMC21968 VANDYKE, K., & SZUSTKIE, C. (1968). AUTOMATED SYSTEMS FOR FLUOROMETRIC DETERMINATION OF NUCLEIC ACIDS BY ETHIDIUM BROMIDE TECHNIQUE. ANALYTICAL BIOCHEMISTRY, 23(1), 109-&.
WoS18 Europe PMC61968 VANDYKE, K., & KATZMAN, P. A. (1968). EFFECT OF PREGNANT MARES SERUM (PMS) ON RNA POLYMERASE ACTIVITY AND PROTEIN SYNTHESIS IN OVARIES OF IMMATURE RATS. ENDOCRINOLOGY, 83(1), 107-+.
WoS9 Europe PMC3 -
Conference Papers
Year Citation 2023 Williams, C., Noll, J., Harnas, D., Parkinson, H., Hewett, D., Wyllie, K., . . . Panagopoulos, V. (2023). Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma. In BLOOD Vol. 142 (pp. 3 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Parkinson, H., Breen, J., Hin, N., Panagopoulos, V., Zannettino, A., Vandyke, K., & Hewett, D. (2023). A Functional Genomic Screen to Identify Novel Genes Involved in Multiple Myeloma Tumour Development. In BLOOD Vol. 142 (pp. 3 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12013 Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION. 2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel™) Inhibits Oteoclast Activity <i>in Vitro</i> and <i>in Vivo</i> Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. 1986 VANDYKE, C., VANDYKE, K., CATERSON, B., SZUSTKIEWICZ, C., & REICH, A. (1986). ENHANCED-DURATION-CHEMILUMINESCENCE-IMMUNOASSAY (EDLIA) USING HORSE RADISH PEROXIDASE-LUMINOL-HYDROGEN PEROXIDE-PARA IODOPHENOL (PIP) - CONFIRMATION AND EXTENSION OF THE SYSTEM. In FEDERATION PROCEEDINGS Vol. 45 (pp. 732). FEDERATION AMER SOC EXP BIOL. 1985 THORNTON, M., VANDYKE, K., VANDYKE, C., & DIBARTOLOMEO, A. (1985). SENSITIVITY DIFFERENCES OF PLATELET ACTIVATING FACTOR (PAF) AND LYSO PAF ON CHEMI-LUMINESCENCE (CL) BETWEEN GRANULOCYTES OF NORMAL AND ARTHRITIC PATIENTS. In FEDERATION PROCEEDINGS Vol. 44 (pp. 1839). FEDERATION AMER SOC EXP BIOL.
WoS11984 PEDEN, D., VANDYKE, K., & EDINBORO, L. (1984). THE DISCONJUGATE INHIBITION OF N-FORMYL-METHIONYL-LEUCINYL-PHENYLALANINE INDUCED NEUTROPHIL CHEMI-LUMINESCENCE AND AGGREGATION BY NORDIHYDROGUIARETIC ACID AND INDOMETHACIN. In FEDERATION PROCEEDINGS Vol. 43 (pp. 953). FEDERATION AMER SOC EXP BIOL. 1984 EDINBORO, L., VANDYKE, K., & CASTRANOVA, V. (1984). EFFECTS OF PLATELET ACTIVATING FACTOR ON MEMBRANE-POTENTIAL AND RESPIRATORY BURST ACTIVITY OF HUMAN-GRANULOCYTES. In FEDERATION PROCEEDINGS Vol. 43 (pp. 461). FEDERATION AMER SOC EXP BIOL.
WoS21983 VANDYKE, K., CASTRANOVA, V., & VANDYKE, C. J. (1983). ANTI-INFLAMMATORY DRUG EFFECTS ON LUMINOL-DEPENDENT CHEMI-LUMINESCENCE (CL) FROM HUMAN-GRANULOCYTES STIMULATED BY CA++ IONOPHORE (A23187) AND BY THE REDUCED OR OXIDIZED FORMS OF A FORMYL PEPTIDE (FMLP OR FMOXLP). In FEDERATION PROCEEDINGS Vol. 42 (pp. 698). FEDERATION AMER SOC EXP BIOL.
WoS11982 VANDYKE, K., ENGLISH, D., PEKOE, G., PEDEN, D., MENGOLI, H., & CASTRANOVA, V. (1982). MULTIPURPOSE RADIOMATIC AUTOMATED FLOW LIQUID SCINTILLATION-COUNTER SYSTEM FOR MEASUREMENT OF BURST OR DELAYED CHEMI-LUMINESCENCE REACTIONS - MODEL-DRUG INHIBITION WITH LUMINOL DEPENDENT MYELOPEROXIDASE REACTION. In FEDERATION PROCEEDINGS Vol. 41 (pp. 1549). FEDERATION AMER SOC EXP BIOL. 1982 PEKOE, G. M., PEDEN, D., & VANDYKE, K. (1982). ANTIOXIDANT EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AGAINST PMN MYELOPEROXIDASE INFLAMMATORY FREE-RADICALS MEASURED BY LUMINOL-ENHANCED CHEMI-LUMINESCENCE (CL). In FEDERATION PROCEEDINGS Vol. 41 (pp. 1549). FEDERATION AMER SOC EXP BIOL. 1981 VANDYKE, K. (1981). DETERMINATION OF WATER HARDNESS RESIDUES ON CLOTHS AFTER TERG-O-TOMETER TESTING. In JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY Vol. 58 (pp. A591). AMER OIL CHEMISTS SOC. 1981 CASTRANOVA, V., JONES, G. S., PHILLIPS, R. M., PEDEN, D., & VANDYKE, K. (1981). ABNORMALITIES ASSOCIATED WITH CHRONIC GRANULOMATOUS-DISEASE. In FEDERATION PROCEEDINGS Vol. 40 (pp. 753). FEDERATION AMER SOC EXP BIOL.
WoS11980 JONES, G. S., WILSON, M. E., VANDYKE, K., & CASTRANOVA, V. (1980). DETERMINATION OF TRANSMEMBRANE POTENTIAL IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES. In FEDERATION PROCEEDINGS Vol. 39 (pp. 2100). FEDERATION AMER SOC EXP BIOL. 1979 UDEINYA, I. J., & VANDYKE, K. (1979). INHIBITION OF PARASITIZATION AND MEMBRANE GLYCOPROTEIN SYNTHESIS IN PLASMODIUM-FALCIPARUM BY TUNICAMYCIN AND 2-DEOXYGLUCOSE. In FEDERATION PROCEEDINGS Vol. 38 (pp. 543). FEDERATION AMER SOC EXP BIOL.
WoS11979 VANDYKE, K., UDEINYA, J., VANDYKE, C., BRISTER, C., & WILSON, M. (1979). LUMINOL-DEPENDENT CHEMI-LUMINESCENCE ANALYSIS (LDCA) OF HUMAN NEUTROPHILS - EFFECT OF ANTI-INFLAMMATORY DRUGS AND ENVIRONMENTAL-POLLUTANTS. In FEDERATION PROCEEDINGS Vol. 38 (pp. 441). FEDERATION AMER SOC EXP BIOL. 1978 WILSON, M. E., TRUSH, M. A., SCHREIBER, R. D., & VANDYKE, K. (1978). LUMINOL-DEPENDENT CHEMILUMINESCENCE ANALYSIS (LDCA) OF ALTERNATIVE PATHWAY DEFECTS IN PREMATURE HUMAN NEONATES. In FEDERATION PROCEEDINGS Vol. 37 (pp. 710). FEDERATION AMER SOC EXP BIOL. 1978 UDEINYA, I. J., & VANDYKE, K. (1978). BLOCKADE BY PURINE-6 SULFONIC-ACID 3N OXIDE OF UPTAKE, PHOSPHORYLATION AND POLYMERIZATION OF HYPOXANTHINE-H-3 BY MALARIA PARASITES. In FEDERATION PROCEEDINGS Vol. 37 (pp. 605). FEDERATION AMER SOC EXP BIOL. 1977 TRUSH, M., VANDYKE, K., ROBINSON, R., URQUILLA, P., SMITH, D., TAYLOR, M., . . . CRAIG, C. R. (1977). EVIDENCE THAT MOST OF CATECHOLAMINES IN CHROMAFFIN GRANULES ARE STORED WITHOUT ASSOCIATED ATP. In FEDERATION PROCEEDINGS Vol. 36 (pp. 383). FEDERATION AMER SOC EXP BIOL. 1977 WILSON, M., TRUSH, M., & VANDYKE, K. (1977). EFFECT OF IONOPHORE A23187 ON CHEMILUMINESCENCE BY HUMAN GRANULOCYTES. In FEDERATION PROCEEDINGS Vol. 36 (pp. 1071). FEDERATION AMER SOC EXP BIOL.
WoS51977 URQUILLA, P. R., VANDYKE, K., & TRUSH, M. (1977). CONTRACTILE EFFECTS OF PYRIMIDINE NUCLEOTIDES IN CANINE CEREBRAL-ARTERIES. In FEDERATION PROCEEDINGS Vol. 36 (pp. 1035). FEDERATION AMER SOC EXP BIOL.
WoS61976 VANDYKE, K., CARTER, G., TRUSH, M., & MAWHINNEY, M. G. (1976). INHIBITORY EFFECT OF 2 DEOXYGLUCOSE AND 5-THIO-D-GLUCOSE ON PHOSPHORYLATION OF ADENOSINE-H-3 AND INCORPORATION INTO NUCLEIC-ACIDS OF MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 35 (pp. 749). FEDERATION AMER SOC EXP BIOL. 1976 TRUSH, M. A., VANDYKE, K., & RAMANAN, S. (1976). INHIBITION OF PHAGOCYTOSIS-LINKED LIGHT-EMISSION FROM HUMAN GRANULOCYTES BY PROMETHAZINE - EXAMPLE OF PHOTOPHARMACOLOGY. In FEDERATION PROCEEDINGS Vol. 35 (pp. 748). FEDERATION AMER SOC EXP BIOL.
WoS11976 URQUILLA, P. R., VANDYKE, K., & ROBINSON, R. (1976). RELAXANT EFFECTS OF ADENINE NUCLEOSIDES AND NUCLEOTIDES ON CANINE CEREBRAL-ARTERIES. In FEDERATION PROCEEDINGS Vol. 35 (pp. 699). FEDERATION AMER SOC EXP BIOL.
WoS31975 VANDYKE, K., & NEWCOMER, C. (1975). EFFECT OF PURINE ANTIMETABOLITES ON PHOSPHORYLATION OF HYPOXANTHINE-H-3 IN ERYTHROCYTE-FREE MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 34 (pp. 807). FEDERATION AMER SOC EXP BIOL.
WoS11975 ROWE, J. N., VANDYKE, K., WESTFALL, D. P., & STITZEL, R. E. (1975). INVITRO SYNTHESIS OF ATP IN GUINEA-PIG VAS-DEFERENS. In FEDERATION PROCEEDINGS Vol. 34 (pp. 739). FEDERATION AMER SOC EXP BIOL.
WoS21974 MANANDHA, M. S., & VANDYKE, K. (1974). PURINE-SALVAGE METABOLISM IN FREE MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 33 (pp. 592). FEDERATION AMER SOC EXP BIOL.
WoS41974 VANDYKE, K., & MANANDHA, M. S. (1974). ULTRASENSITIVE DELAYED LUMINESCENCE ANALYSIS (DLA) FOR ALL NATURALLY OCCURRING NUCLEOTIDE TRIPHOSPHATES. In FEDERATION PROCEEDINGS Vol. 33 (pp. 480). FEDERATION AMER SOC EXP BIOL. 1974 MANANDHA, M. S., VANDYKE, K., & ROBINSON, R. L. (1974). METABOLISM OF GUANOSINE-H-3 IN PERFUSED HEART. In FEDERATION PROCEEDINGS Vol. 33 (pp. 385). FEDERATION AMER SOC EXP BIOL. 1973 VANDYKE, K., & CARTER, G. W. (1973). POSSIBLE NEW ROLE FOR ADRENAL-MEDULLA - READY SUPPLY OF PURINES FOR HEART AND LUNGS. In FEDERATION PROCEEDINGS Vol. 32 (pp. 740-&). FEDERATION AMER SOC EXP BIOL.
WoS21972 STEVENS, P., STITZEL, R. E., VANDYKE, K., & ROBINSON, R. L. (1972). SPECIES DIFFERENCE IN DEMONSTRATION OF NUCLEOTIDE LABELING OF CATECHOLAMINE-ATP COMPLEX IN CHROMAFFIN GRANULES OF ADRENAL-MEDULLA. In FEDERATION PROCEEDINGS Vol. 31 (pp. A521-&). FEDERATION AMER SOC EXP BIOL. 1971 VANDYKE, K., STEVENS, P., & ROBINSON, R. L. (1971). DEMONSTRATION OF DYNAMIC NATURE OF ATP IN CATECHOLAMINE-ATP COMPLEX OF ADRENAL GLAND. In FEDERATION PROCEEDINGS Vol. 30 (pp. A445-&). FEDERATION AMER SOC EXP BIOL. 1970 LANTZ, C., & VANDYKE, K. (1970). SELECTIVE EFFECT OF INTERCALATING DRUGS ON ACTIVITY OF RNA POLYMERASE OF MALARIAL PARASITES. In FEDERATION PROCEEDINGS Vol. 29 (pp. A808-+). FEDERATION AMER SOC EXP BIOL.
WoS11969 VANDYKE, K., MCCARTHY, J., FURNER, R., & STITZEL, R. (1969). PATHOLOGICAL EFFECTS OF MALARIA INFECTION ON HOST MICROSOMAL DRUG-METABOLIZING ENZYMES. In FEDERATION PROCEEDINGS Vol. 28 (pp. 366-&). FEDERATION AMER SOC EXP BIOL.
WoS11969 BERGHEI, P., VANDYKE, K., MCCLELLA, T., SZUSTKIE, C., & LANTZ, C. (1969). INHIBITORY EFFECTS OF ANTIMETABOLITES AND INTERCALATING ANTIBIOTICS ON INCORPORATION OF ADENOSINE-8-3HINTO NUCLEIC ACIDS OF MALARIAL PARASITE. In FEDERATION PROCEEDINGS Vol. 28 (pp. 361-&). FEDERATION AMER SOC EXP BIOL. 1968 VANDYKE, K., STITZEL, R., MCCLELLA, T., & SZUSTKIE, C. (1968). A SENSITIVE AND SPECIFIC DETERMINATION OF ATP BY AN AUTOMATED METHOD. In FEDERATION PROCEEDINGS Vol. 27 (pp. 841-&). FEDERATION AMER SOC EXP BIOL. 1968 VANDYKE, K., TREMBLAY, G. C., SZUSTKIE, C., & SAXE, L. H. (1968). PRELIMINARY STUDIES OF PURINE AND PYRIMIDINE INCORPORATION AND BIOSYNTHESIS INTO NUCLEIC ACIDS OF RAT BLOOD PARASITIZED BY PLASMODIUM BERGHEI. In JOURNAL OF PROTOZOOLOGY Vol. S 15 (pp. 23-&). SOC PROTOZOOLOGISTS.
WoS201967 DAVIS, S., & VANDYKE, K. (1967). EFFECT OF PROSCILLARIDIN IN COMBATTING SIMULATED CONGESTIVE HEART FAILURE AND DISAPPEARANCE OF TRITIATED DRUG FROM SEVERAL TISSUES. In FEDERATION PROCEEDINGS Vol. 26 (pp. 782-&). FEDERATION AMER SOC EXP BIOL. 1967 VANDYKE, K., & SZUSTKIE, C. (1967). A SENSITIVE AND SPECIFIC DETERMINATION OF SOME L-ALPHA AMINO ACIDS BY AN AUTOMATED METHOD. In FEDERATION PROCEEDINGS Vol. 26 (pp. 469-&). FEDERATION AMER SOC EXP BIOL. 1966 VANDYKE, K., & KATZMAN, P. A. (1966). EFFECT OF PMS ON ACTIVITY OF RNA POLYMERASE AND SYNTHESIS OF NUCLEIC ACIDS IN OVARIES OF IMMATURE RATS. In FEDERATION PROCEEDINGS Vol. 25 (pp. 286-&). FEDERATION AMER SOC EXP BIOL.
WoS1 -
Conference Items
Year Citation 2023 Cheney, E. A. J., Harnas, D., Noll, J., Vandyke, K., Zannettino, A., & Hewett, D. (2023). Towards an IMiD sensitive C57BL/KaLwRij murine model of multiple myeloma. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. 2023 Trainor, L. J., Cantley, M. D., King, C., Plakhova, N., Skinner, M., Chai, R., . . . Zannettino, A. (2023). Profiling of patient bone marrow adipocytes in the myeloma microenvironment. Poster session presented at the meeting of Abstracts of the 20th Annual Meeting and Exposition of the International Myeloma Society (IMS 2023), as published in Clinical Lymphoma Myeloma and Leukemia. Athens, Greece: Elsevier.
2019 Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2019 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
| Date | Role | Grant | Funding Body | Amount |
|---|---|---|---|---|
| 2021-2023 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cancer Australia/Cure Cancer Australia/Snowdome Foundation | AUD$198,813 |
| 2019-2022 | CoI | Strategic Ecosystem Research Partnerships | Leukaemia Foundation | AUD$596,198 |
| 2019 - 2021 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cancer Australia/Cure Cancer Australia/Leukaemia Foundation | AUD$198,596 |
| 2017-2018 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cure Cancer Australia | AUD$199,454 |
| 2016 | CIA | Project Grant | Royal Adelaide Hospital Contributing Haematologists' Committee | AUD$25,000 |
| 2016 | CIE | Project Grant | Royal Adelaide Hospital Research Fund | AUD$50,000 |
| Date | Title | Funding Body | Amount |
|---|---|---|---|
| 2018-2021 | Beat Cancer Early Career Cancer Research Fellowship | Cancer Council SA | AUD$240,000 |
| 2013-2015 | Mary Overton Early Career Fellowship | Royal Adelaide Hospital | AUD$252,000 |
| 2013-2015 | Veronika Sacco Early Career Fellowship | Florey Medical Research Foundation | AUD$222,003 |
| 2011 | MMRF Research Fellow Award | Multiple Myeloma Research Foundation (USA) | AUD$74,146 |
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Co-Supervisor Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development Doctor of Philosophy Doctorate Part Time Miss Mackenzie Rose Skinner 2020 Principal Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Part Time Miss Laura Joy Trainor 2020 Co-Supervisor Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson 2020 Principal Supervisor Development and assessment of novel drug delivery strategies to improve the treatment of multiple myeloma Doctor of Philosophy Doctorate Full Time Ms Sadia Munir -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Co-Supervisor The Role of Bone Marrow Mesenchymal Stromal Cell Senescence in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova 2019 - 2021 Co-Supervisor Macrophages, Myeloma, Mouse Models and Methodologies Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman 2017 - 2020 Principal Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig 2013 - 2017 Co-Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong 2012 - 2018 Co-Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik
-
Committee Memberships
Date Role Committee Institution Country 2015 - ongoing Member Women's and Children's Hospital Foundation Research Grants Committee - - 2014 - ongoing Member Australian Society for Medical Research SA Committee - - -
Memberships
Date Role Membership Country 2021 - ongoing Member International Myeloma Society United States 2019 - ongoing Member Australasian Leukaemia and Lymphoma Group Australia 2015 - ongoing - Haematology Society of Australia and New Zealand - 2014 - ongoing Member Australian Society for Medical Research -
Connect With Me
External Profiles
